STOCK TITAN

Aquestive Therapeutics, Inc. - $AQST STOCK NEWS

Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: $AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aquestive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aquestive Therapeutics's position in the market.

Rhea-AI Summary
Aquestive provides update on development timeline for oral epinephrine product candidate, Anaphylm
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
Rhea-AI Summary
FDA accepts Aquestive's NDA for Libervant Buccal Film in pediatric patients between two and five years of age with a PDUFA goal date of April 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
-
Rhea-AI Summary
Aquestive Therapeutics to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) released positive topline data from its latest clinical pilot trial for Anaphylm™ (epinephrine) Sublingual Film. The 103 study demonstrated that Anaphylm delivers epinephrine systemically as effectively as commercially available autoinjectors or the manual intramuscular injection. The product was considered safe and well-tolerated with no serious adverse events. The company plans to submit the pivotal PK clinical study protocol to the FDA in early August and anticipates commencement of its definitive pivotal PK clinical trial in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. will present two posters at the Aspen Allergy Conference, recapping positive topline data from pharmacokinetic and pharmacodynamic studies of their Anaphylm epinephrine sublingual film. The film is being developed as an oral treatment for severe allergic reactions. The presentations will focus on the comparison of the film with intra-muscular epinephrine and the impact of food exposure on its pharmacokinetics. The conference will take place from July 30 to August 3 in Aspen, CO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences
-
Rhea-AI Summary
Aquestive Therapeutics, Inc. will present two posters at the Global Food Allergy Prevention Summit, showcasing positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm epinephrine sublingual film. Anaphylm has the potential to be the first oral candidate for the emergency treatment of severe allergic reactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Aquestive Therapeutics, Inc.

Nasdaq:AQST

AQST Rankings

AQST Stock Data

281.31M
65.02M
5.03%
34.33%
2.53%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
WARREN

About AQST

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.